KRAS and melanoma: Further, only 1.6% (3/186) of melanoma cases in the Memorial Sloan Kettering MSK-IMPACT dataset were KRAS mutant, significantly lower than in our early brain metastasis discovery cohort (p = 0.0327, logistic regression Wald t test).